Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.

BACKGROUND There are limited data about the quality of immune-related adverse event (irAE) reporting in immune checkpoint inhibitor (ICI) clinical trial publications. METHODS A systematic search of citations from Medline, EMBASE and Cochrane databases identified prospective clinical trials involving ICIs in advanced solid tumors from 2003 to 2013. A 21-point quality score (QS) was adapted fro...

Renal Toxicity Related to Immune Checkpoint Inhibitors

As early as the 18th century, physicians noticed that some cancer patients went into remission after developing fevers from infections. This led to the idea that the immune system, which protects from infection, might also fight cancer. What is now known as “immunotherapy” is a treatment that targets the immune system to recognize and eradicate cancer cells. Modern immunotherapy has focused on ...

Tusanqi-Related Sinusoidal Obstruction Syndrome in China

(1) Duplicates amon (2) Duplicate public journals; Editor: Giovanni Tarantino. Received: April 5, 2015; revised: May 4, 2015; accepted: May 6, 2015. From the Department of Gastroenterology, General, Hospital of Shenyang Military Area (XW, XQ, XG); and Postgraduate College, Liaoning University of Traditional Chinese Medicine (XW), Shenyang, China. Correspondence: Prof Xiaozhong Guo, MD, PhD, and...

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.

Hepatic sinusoidal obstruction syndrome following hematopoietic stem cell transplantation.

J.m., a 43-year-old man with acute myelogenous leukemia with a monosomy 7 cytogenetic abnormality, received an allogeneic hematopoietic stem cell transplantation (HscT) from his human leukocyte antigen– matched brother. Past treatments included idarubicin and cytarabine induction therapy followed by a cycle of high-dose cytarabine. J.m. was in complete remission prior to the HscT. The condition...